EDEM3

Across TCGA pan-cancer cohorts, EDEM3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EDEM3 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher EDEM3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EDEM3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LIHC, UCEC, and PRAD are the cancer types where EDEM3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.184	0.719	<.001	27	view →
UCEC	DFS	Median	All	0.906	0.618	.026	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	DFS	Median	All	0.098	0.710	<.001	6	view →
SKCM	DFS	Median	All	0.839	0.195	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EDEM3–LIHC (OS)

Open the LIHC breakdown →